PKX BIO
Live / Applied — Final refusal mailed (as of 11 Mar 2026)
What this means for you
Not registered yet, but its 08 Aug 2025 filing date beats anything filed after it. If it registers, the owner can stop confusingly similar uses in the classes it covers.
Record
- Serial number
- 99328081
- Mark type
- Stylized text
- Filed
- 08 Aug 2025
- Attorney of record
- Aaron D. Hendelman
Goods and services
- Class 001 — Chemicals: Chemicals, namely, cyclodextrins for industrial purposes; preparations derived from cyclodextrins, namely, chemicals for industrial purposes and active principles in the nature of active chemical ingredients, complexed by cyclodextrins, for use in the manufacture of pharmaceuticals and medicines; chemicals, namely, cyclodextrins and cyclodextrin derivatives for use in the chemical, plastics, paper, agricultural, horticultural, insulation, packaging, pharmaceutical, cosmetic, fragrance, textile, leather, healthcare, food and paint industries; active pharmaceutical ingredients, namely, salts for use in the manufacture of pharmaceuticals and medicines
- Class 005 — Pharmaceuticals: pharmaceutical preparations and substances for the treatment of viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric and immune system-related diseases and disorders; drug delivery devices, namely, subcutaneous pumps filled with medication for the delivery of medication for viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric and immune system-related diseases and disorders
- Class 010 — Medical apparatus: drug delivery devices sold empty, namely, subcutaneous pumps for the delivery of medication
- Class 042 — Scientific and technological services: medical and scientific research in the fields of autoimmune, cardiovascular, central nervous system, endocrine, gastrointestinal, genetic, infectious, inflammatory, kidney, liver, menopausal, metabolic, musculoskeletal, neurodegenerative, neurological, neuromuscular and viral diseases and disorders; providing pharmaceutical formulation platforms, namely, proprietary chemical compositions and pharmaceutical development and manufacturing methods for improving the physical and chemical characteristics, namely, solubility and stability, of small molecules for controlled delivery of therapeutic agents; medical and scientific research and development in relation to pharmaceuticals and drug delivery platforms; providing scientific information, advisory, and consultancy services relating to pharmaceuticals and drug delivery devices therefor; pharmaceutical research and development; drug discovery services; research and development in the field of computational biology, bioinformatics, genomics, biotechnology, immunology and pharmaceuticals; biomedical research and pharmaceutical development services, namely, scientific study and research in the fields of medicine, biomedical technology, and genetics; technical scientific consultation and product development for others in the field of biotechnology and development of pharmaceuticals
- Class 044 — Medical, beauty and agricultural services: providing medical information, advisory, and consultancy services relating to pharmaceuticals and drug delivery devices therefor
Owner
- Bexson Biomedical, Inc., Santa Barbara, CA, US
Prosecution history
- 11 Mar 2026 — NOTIFICATION OF FINAL REFUSAL EMAILED
- 11 Mar 2026 — FINAL REFUSAL E-MAILED
- 11 Mar 2026 — FINAL REFUSAL WRITTEN
- 02 Feb 2026 — TEAS/EMAIL CORRESPONDENCE ENTERED
- 02 Feb 2026 — CORRESPONDENCE RECEIVED IN LAW OFFICE
- 02 Feb 2026 — TEAS RESPONSE TO OFFICE ACTION RECEIVED
- 23 Dec 2025 — NOTIFICATION OF NON-FINAL ACTION E-MAILED
- 23 Dec 2025 — NON-FINAL ACTION E-MAILED
- 23 Dec 2025 — NON-FINAL ACTION WRITTEN
- 22 Dec 2025 — ASSIGNED TO EXAMINER
- 18 Dec 2025 — NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
- 08 Aug 2025 — APPLICATION FILING RECEIPT MAILED
- 08 Aug 2025 — NEW APPLICATION ENTERED